Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1309988

registered interest
date	19/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Screening
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the (1) accuracy, and (2) usefulness, of lateral flow tests, following reports that the rate of false positives returned by these tests has increased as the prevalence of COVID-19 has fallen.
tabling member printed	Lord Balfe
uin	HL15034
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>New analysis of community testing data shows lateral flow device (LFD) tests to have a specificity of at least 99.9%. For every 1,000 LFD tests carried out, there is less than one false positive result. Rapid testing using LFDs detects cases quickly in under 30 minutes, meaning positive cases can isolate immediately, breaking chains of transmission.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:35:15 answering member 4708 label Biography information for Lord Bethell
tabling member	4302 label Biography information for Lord Balfe

1309307

registered interest
date	15/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Conservative Party
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many meetings Ministers in the Department of Health and Social Care have had since March 2020 with (1) individuals, or (2) representatives of companies, that have made donations to the Conservative Party; and what the purpose of any such meeting was.
tabling member printed	Lord Scriven
uin	HL14980
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The information is not held in the format requested and could only be obtained at disproportionate cost.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:34:54 answering member 4708 label Biography information for Lord Bethell
tabling member	4333 label Biography information for Lord Scriven

1309187

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of (1) the efficiency of the roll-out of COVID-19 vaccinations in each region of England, and (2) how that compares with the roll-out of such vaccinations in (a) Northern Ireland, (b) Scotland, and (c) Wales.
tabling member printed	Lord Dodds of Duncairn
uin	HL14912
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>Each region within England and each of the devolved administrations have different population levels, clinical needs and logistical challenges to meet when deploying COVID-19 vaccines. The Government assesses the efficiency of the programme against these and other factors.</p><p>The Government works with the devolved administrations to ensure the vaccine programme is rolled out as quickly and efficiently as possible in each region. Allocation of vaccines is based upon the Barnett Formula. This ensures that all of the United Kingdom receives a fair share of vaccines. Approximately 27.1 million people in England, 838,000 in Northern Ireland, 2.6 million people in Scotland and 1.6 million in Wales have now received their first dose.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:33:23 answering member 4708 label Biography information for Lord Bethell
tabling member	1388 label Biography information for Lord Dodds of Duncairn

1309195

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the response by Lord Bethell on 19 January (HL Deb, cols 1080–4), what progress they have made towards developing research projects on brain tumours, and in particular on young people with brain tumours.
tabling member printed	Baroness Jay of Paddington
uin	HL14920
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>As part of the Tessa Jowell Brain Cancer Mission, the National Institute for Healthcare Research has received 69 applications, 10 of which have been funded and a further seven are under consideration. One of the funded applications is focused solely on children and others include young people.</p><p> </p> answering member printed Lord Bethell question first answered 23/04/2021 12:58:06 answering member 4708 label Biography information for Lord Bethell
tabling member	1970 label Biography information for Baroness Jay of Paddington

1309200

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking (1) to address the efficacy of the 12 week gap between doses of the COVID-19 vaccine for blood cancer patients, and (2) to protect such patients who have received one dose of a COVID-19 vaccine from exposure to COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL14925
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>To optimise the period between doses of the COVID-19 vaccine for all cancer patients, the timing of second dose administration can be varied on clinical advice according to the patient’s individual situation. For immunosuppressed cancer patients, the second dose can be given at different timescales to the 12 weeks routinely in place for most people.</p><p>Cancer patients undergoing immunosuppressive therapies, where clinically appropriate, should receive their vaccine doses at least two weeks prior to commencing therapy when their immune system is better able to respond. To maximise vaccine efficacy this may entail offering the second dose between the recommended minimum for that vaccine - three or four weeks after first dose - and the recommended maximum of 12 weeks. Although shielding has been paused, current guidance for clinically extremely vulnerable people including immunosuppressed cancer patients advises them to follow the rules and guidance that are in place for the wider population.</p> answering member printed Lord Bethell grouped question UIN HL14927 question first answered 23/04/2021 12:40:19 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn

1309202

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking (1) to reduce the gap between doses of the COVID-19 vaccine for cancer patients, and (2) to protect such patients who have received one dose of a COVID-19 vaccine from exposure to COVID-19.
tabling member printed	Lord Mendelsohn
uin	HL14927
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>To optimise the period between doses of the COVID-19 vaccine for all cancer patients, the timing of second dose administration can be varied on clinical advice according to the patient’s individual situation. For immunosuppressed cancer patients, the second dose can be given at different timescales to the 12 weeks routinely in place for most people.</p><p>Cancer patients undergoing immunosuppressive therapies, where clinically appropriate, should receive their vaccine doses at least two weeks prior to commencing therapy when their immune system is better able to respond. To maximise vaccine efficacy this may entail offering the second dose between the recommended minimum for that vaccine - three or four weeks after first dose - and the recommended maximum of 12 weeks. Although shielding has been paused, current guidance for clinically extremely vulnerable people including immunosuppressed cancer patients advises them to follow the rules and guidance that are in place for the wider population.</p> answering member printed Lord Bethell grouped question UIN HL14925 question first answered 23/04/2021 12:40:19 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn

1309214

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Swimming Pools
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the findings of the study undertaken by Imperial College London and Water Babies, reported on 12 April, which found that swimming pool water can inactivate the COVID-19 virus in 30 seconds in the right conditions.
tabling member printed	Lord Storey
uin	HL14942
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>Public Health England has not made an assessment.</p> answering member printed Lord Bethell question first answered 23/04/2021 12:58:12 answering member 4708 label Biography information for Lord Bethell
tabling member	4238 label Biography information for Lord Storey

1309226

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether the Joint Committee on Vaccination and Immunisation has (1) been sent, and (2) discussed, the peer-reviewed Sars CoV-2 for cancer patients (SOAP) study on the efficacy of COVID-19 vaccines for cancer patients.
tabling member printed	Lord Mendelsohn
uin	HL14928
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) was sent the pre-print article on 15 March 2021, which was discussed at its meeting on 16 March 2021. The minutes of the meeting will be published in due course.</p><p>The JCVI has not made any public statements on this study. JCVI has reassured the public that lower immune responses following vaccination do not necessarily infer weaker or absent protection against disease.</p> answering member printed Lord Bethell grouped question UIN HL14929 question first answered 23/04/2021 12:39:56 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn

1309227

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government, further to the Sars CoV-2 for cancer patients (SOAP) study on the efficacy of COVID-19 vaccines for cancer patients, what plans the Joint Committee on Vaccination and Immunisation has (1) to change, and (2) to apologise for, its statements about (a) the scientific efficacy of the size of study, (b) that study's evaluation of T Cell responses, and (c) that study's lack of consistency of immunological markers, and its conclusion that the study provides no data of relevance for policy recommendations to be made.
tabling member printed	Lord Mendelsohn
uin	HL14929
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) was sent the pre-print article on 15 March 2021, which was discussed at its meeting on 16 March 2021. The minutes of the meeting will be published in due course.</p><p>The JCVI has not made any public statements on this study. JCVI has reassured the public that lower immune responses following vaccination do not necessarily infer weaker or absent protection against disease.</p> answering member printed Lord Bethell grouped question UIN HL14928 question first answered 23/04/2021 12:39:56 answering member 4708 label Biography information for Lord Bethell
tabling member	4286 label Biography information for Lord Mendelsohn

1308734

registered interest
date	13/04/2021
answering body	Northern Ireland Office
answering dept id	21
answering dept short name	Northern Ireland
answering dept sort name	Northern Ireland
hansard heading	Terrorism: Northern Ireland
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what discussions they have had with the Northern Ireland Executive about the financing of the victims' pension scheme.
tabling member printed	Lord Dodds of Duncairn
uin	HL14867
answer	answer is ministerial correction date of answer 23/04/2021 answer text <p>The Secretary of State for Northern Ireland regularly meets with NI Executive Ministers about a range of issues, including funding for the Troubles Permanent Disablement Scheme. He met with Executive Ministers on 23 February and on 7 April about this specific issue, and he has written to the NI Executive offering access to NDNA funds that will help the Executive manage the cost of the scheme.</p><p> </p><p>The UK Government welcomes the undertaking given to the Court on 12 April that the Executive will make the necessary funding available to ensure eligible victims receive the payments to which they are legally entitled.</p><p> </p><p>There is nothing now standing in the way of the Executive delivering the scheme as set out in legislation, and we will continue to prioritise supporting the Executive’s delivery of this scheme.</p><p> </p> answering member printed Viscount Younger of Leckie question first answered 23/04/2021 12:28:28 answering member 4169 label Biography information for Viscount Younger of Leckie
tabling member	1388 label Biography information for Lord Dodds of Duncairn